CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16 enrolled
Drug / intervention
Rifampicin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02329405
NCT02329405Phase 4Completed
CompareCT.gov

PXR-aktivaation Vaikutus Maksan Rasvoittumiseen

University of Oulu·interventional·Posted Dec 31, 2014·Updated Nov 1, 2017

In Brief

A Phase 4 clinical trial evaluating Rifampicin and Placebo for Non-alcoholic Fatty Liver Disease. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This study investigates the effects of pregnane X receptor (PXR) activation on hepatic fat content in healthy volunteers. Rifampicin (an antibiotic and also an efficient PXR activator) and placebo will be given for a week to volunteers. Hepatic fat content is measured with magnetic resonance imaging and blood samples are collected at the end of each study arm. The investigators' hypothesis is that rifampicin causes accumulation of fat to the liver.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-alcoholic Fatty Liver Disease
CountriesFinland
CollaboratorsOulu University Hospital

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 31, 2014
Enrollment StartDec 1, 2014
Primary CompletionJan 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.5 years ago

Interventions

Rifampicindrug

Placebodrug